Clinical trial · Interventional
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study
NCT06292286CI-TRIAL-00090874SCENICrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Ovarian Carcinoma | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab or biosimilar | Drug | Bevacizumab | ALIAS |
| Carboplatin or cisplatin | Procedure | — | UNRESOLVED |
| Cytoreductive surgery | Procedure | — | UNRESOLVED |
| Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy and surgery arm
- description
- Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.
- interventionNames
- Procedure: Carboplatin or cisplatin
- Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
- Drug: Bevacizumab or biosimilar
- Procedure: Cytoreductive surgery
Primary outcomes (1)
- measure
- Complete resection rate
- timeFrame
- 12 months
- description
- Rate of complete resection at the time of operation
Secondary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma * \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting * Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy * Upfront SCR not feasible * Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment. * Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment. Exclusion Criteria: * Non-epithelial or borderline tumors are excluded * Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded. * Patients using more than one line of chemotherapy are excluded. * Patients who have platinum-resistant or refractory recurrence are excluded. * Patients having second relapse or beyond are excluded. * Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment
References
Publications (0)
Data not yet available
No reference posted for this study.